2-(4-甲基-1,3-噻唑-2-基)乙醇 | 333385-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-甲基-1,3-噻唑-2-基)乙醇
• 中文别名: α1-甲基-4-[2-(甲硫基)乙基]-2,5-二羰基咪唑烷-1,3-二(丙酰肼)
• 英文名称: 4-methyl-5-thiazoleethanol
• 英文别名: methylhydroxyethyl thiazole；2-(4-methyl-2-thiazolyl) ethanol；2-(4-Methyl-thiazolyl-(2))-ethanol；2-(4-Methylthiazol-2-yl)ethanol；2-(4-methyl-1,3-thiazol-2-yl)ethanol
• CAS: 333385-00-5
• 化学式: C₆H₉NOS
• 分子量: 143.21
• InChiKey: XRQBCUVCPHPWME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-(4-甲基-1,3-噻唑-2-基)乙醇 在 氢氧化钾 作用下， 生成 2-乙基-4-甲基噻唑
  参考文献：
  名称：

  Process for preparing vinylthiazoles

  摘要：

  公开号：

  US02532573A1

文献信息

• [EN] ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTI-MICROBIENS
  申请人：UNIV RUTGERS

  公开号：WO2013142712A1

  公开（公告）日：2013-09-26

  The invention provides compounds of formual (I): wherein R1-R7 and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.

  该发明提供了式(I)的化合物：其中R1-R7和W具有规范中定义的任何值，以及其盐。这些化合物具有良好的溶解性，并可用于治疗细菌感染。
• [EN] THIAZOLO [5, 4-B] PYRIDINE AND OXAZOLO [5, 4-B] PYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE THIAZOLO [5, 4-B] PYRIDINE ET D'OXAZOLO [5,4-B] COMME AGENTS ANTIBACTÉRIENS
  申请人：ASTRAZENECA AB

  公开号：WO2009147431A1

  公开（公告）日：2009-12-10

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化学式（I）的化合物及其药用可接受的盐。还描述了它们的制备方法、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。
• [EN] ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS<br/>[FR] COMPOSÉS DE (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE ET DE (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2010118852A1

  公开（公告）日：2010-10-21

  wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  提供其中的化学式：其中，要么X是N且Y是CR5，要么X是C且Y是S；Z从N和CH中选择；R1从H和Me中选择；R2从H、OH、OMe和Me中选择；每个R3独立地从C1-3烷基、F、Cl、Br、CF3和NH2中选择；R4从Me、 、NO2和CHF2中选择；R5从H、Me和 中选择；R6从H和Me中选择；p为0-3。提供了包含它们的组合物，它们在治疗中的应用，例如在结核病的治疗中，以及制备这些化合物的方法。
• Amino nicotinate derivatives as glucokinase (GLK) modulators
  申请人：Hayter Raymond Barry

  公开号：US20070112040A1

  公开（公告）日：2007-05-17

  The invention is related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, useful in the treatment of a disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.

  本发明涉及一种新的化合物Formula (I)或其盐、溶剂或前药，其中R1、R2、R3、n和m如规范所述，可用于治疗通过葡萄糖激酶（GLK）介导的疾病或病情，例如2型糖尿病。本发明还涉及制备Formula (I)化合物的方法及其作为药物治疗通过葡萄糖激酶介导的疾病的用途。
• NEW COMPOUND 255
  申请人：Ghorpade Sandeep Raghunath

  公开号：US20100137303A1

  公开（公告）日：2010-06-03

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了化学式(I)的化合物及其药物可接受的盐。还描述了制备它们的过程，包含它们的制药组合物，以及它们作为药物用于治疗细菌感染的用途。